LADAR 6000: good but time consuming

Article

Although the LADAR 6000 (Alcon) is accurate and safe, the need for pharmacological mydriasis and the use of a nomogram result in a more time consuming surgical procedure.

Although the LADAR 6000 (Alcon) is accurate and safe, the need for pharmacological mydriasis and the use of a nomogram result in a more time consuming surgical procedure, according to Joaquim Murta and colleagues from Coimbra University, Portugal.

A total of 300 consecutive eyes underwent refractive surgery with the LADAR 6000. Of those, 245 were submitted to photorefractive keratectomy (PRK) to correct a manifest spheroequivalent refractive error (MSRE) of -5.5+4.3 D, with a cylinder ranging from -4.50 to +3.50 D. Fifty-five eyes were submitted to LASIK using the Zyoptix XP microkeratome (Bausch & Lomb) to correct MSRE of -0.75 to -9.29 with a cylinder ranging from 0.00 to -5.50 D.

Following PRK, uncorrected visual acuity (UCVA) was 0.9, best spectacle corrected visual acuity (BSCVA) was 1.0 and MSRE was 0.00. The eyes which underwent LASIK reached a UCVA of 0.7, a BSCVA of 0.9 and a MSRE of 0.4. Just one eye lost two lines of BSCVA due to adenoviral keratoconjunctivitis.

Dr Murta concluded that the LADAR 6000 offers good results but is a time consuming procedure.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.